COMMUNIQUÉS West-GlobeNewswire

Groundbreaking therapy for advanced heart failure: Repairon Strengthens Executive Leadership with Appointment of Detlef Schumann, Ph.D. as Chief Operating Officer
19/10/2026
Biotech executive brings global leadership and operations experience to speed clinical development, expand operations, and carry out strategic growth plans. GÖTTINGEN, Germany and PROVIDENCE, R.I., Oct. 19, 2026 (GLOBE [...]
Une thérapie révolutionnaire pour l’insuffisance cardiaque avancée : Repairon renforce son équipe de direction avec la nomination de Detlef Schumann, Ph.D., au poste de directeur des opérations
19/10/2026
Ce dirigeant du secteur biotechnologique apporte une expérience internationale en matière de direction et d’opérations, visant à accélérer le développement clinique, à étendre les activités et à mettre en œuvre des [...]
Xealth to Lead Session on AI Applications and Digital Technologies Reshaping Healthcare at IHF World Congress
19/10/2026
SEOUL, South Korea, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Xealth , the leader in digital health orchestration and deployment, today announced that Xealth CEO Mike McSherry will chair a session on innovative applications of [...]
Maxim Hair Restoration, a Leading FUE Hair Transplant Provider, Named a 2026 Best of America Small Business Awards Winner
19/10/2026
BASA Awards® recognizes Maxim in the Health Care & Medical Center category New York City, NEW YORK, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Maxim Hair Restoration has been named among the winners of the 2026 Best of [...]
Kane to Showcase revyve® at Wounds Canada National Hybrid Conference
19/10/2026
Engaging Canadian wound-care professionals, presenting data and discussing biofilm management in clinical practice WINNIPEG, Manitoba, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “ [...]
Jemperli (dostarlimab) Approved in the U.S. as First and Only Immunotherapy for Adults with MSI-H/dMMR Locally Advanced Rectal Cancer
19/10/2026
Approval based on AZUR-1 data showing significant proportion of participants with no detectable signs of cancer one year or more after treatment No disease recurrences reported among responders after median follow up of [...]
Daré Bioscience Sponsors HERmedicine Educational Program for Clinicians on Managing Menopause After Breast Cancer
19/10/2026
Premier sponsorship of the HERmedicine and OncoMenopause Consortium ® program underscores Daré Bioscience's commitment to addressing unmet women’s health needs, including for women affected by breast cancer The program [...]
Beacon Biosignals Partners with Project Sleep to Shorten the Path to Diagnosis for People with Idiopathic Hypersomnia and Narcolepsy
19/10/2026
The partnership connects Beacon's AI-driven neurotechnology with the patient-led advocacy community, expanding access to diagnosis and bringing patient voices directly into clinical research BOSTON, Oct. 19, 2026 (GLOBE [...]
ProSomnus Announces Significant Scientific, Technical, and Advocacy Updates
19/10/2026
World-Renowned Sleep Medicine Leaders Join ProSomnus Medical Advisory Board, RPMO₂ Enhancements, Published FLOSAT Study Results, and Scientific Contributions at CHEST 2026 SAN FRANCISCO, Oct. 19, 2026 (GLOBE NEWSWIRE [...]
RxSight Appoints Eye Care Industry Leaders to Drive Commercial Transformation
19/10/2026
ALISO VIEJO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced the appointments of Taryn Conway as Chief Commercial Officer and Frank Shields as Executive Vice President of Sales and [...]
VIVUS Announces Positive Outcome of European Procedure to Extend QSIVA® (Phentermine/Topiramate MR) to Adolescents with Obesity
19/10/2026
— Landmark European approval will grant young patients and families an evidence-based therapy alongside lifestyle interventions AMSTERDAM, Oct. 19, 2026 (GLOBE NEWSWIRE) -- VIVUS BV, a subsidiary of VIVUS LLC, a [...]
Final Safety, Pharmacokinetic and Pharmacodynamic Data from COL-5671 Phase 1 Clinical Study Presented at UEGW
19/10/2026
COL-5671, a highly selective oral SIK3 inhibitor, demonstrated a favorable safety and pharmacokinetic (PK) profile Pharmacodynamic (PD) data indicate potent TNFα suppression at low doses , with even greater IL-23 [...]
TerrAscend to Host Third Quarter 2026 Earnings Conference Call
19/10/2026
TORONTO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- TerrAscend Corp. (the "Company") (TSX: TSND) (OTCQX: TSNDF), a leading North American cannabis operator, today announced that it will host a scheduled conference call to [...]
XBiotech Announces Positive Phase II Final Efficacy Results from Investigator-Sponsored TASKIN Trial in Refractory Metastatic Colorectal Cancer
19/10/2026
Investigator-sponsored study funded by the French National Cancer Institute (INCa) meets pre-specified primary efficacy success criterion with 61.3% 12-month overall survival. Exploratory Subgroup analysis reveals [...]
23andMe Research Institute to Showcase Scientific Impact and Expanded Research Capabilities at ASHG 2026
19/10/2026
New research and capabilities highlight the power of more than 11 million consented research participants PALO ALTO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- At the American Society of Human Genetics (ASHG) 2026 Annual [...]
PacBio and Verily Health Announce Multi-Year Strategic Collaboration to Scale Long-Read Genomics for Biomedical AI
19/10/2026
Verily Pre will connect PacBio HiFi Sequencing with governed cloud analysis, multimodal health data and AI-ready research workflows MENLO PARK, Calif. and DALLAS, Oct. 19, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB [...]
BioCardia Announces FDA Acceptance of De Novo Pre-Submission Package for Helix™ Catheter Marketing Clearance FDA Substantive Review and Meeting Expected this Quarter
19/10/2026
SUNNYVALE, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA] , a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced [...]
Standard Dental Labs Signs $10 Million Equity Purchase Agreement with Twenty Four Capital
19/10/2026
Facility gives the Company discretion to access equity capital over time to support its Florida dental laboratory strategy ORLANDO, Fla., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Standard Dental Labs Inc. (OTCQB: TUTH) (“SDL” [...]
Phase 3 trial in China successfully confirms ACARIZAX® safety and efficacy in patients with house dust mite allergy
19/10/2026
Inside Information Phase 3 trial with ACARIZAX ® in Chinese participants met the primary objective and showed efficacy in line with previous trials, after only 24-28 weeks of treatment. ACARIZAX ® was shown to be safe [...]

Pages